PubMed İndeksli Açık & Kapalı Erişimli Yayınlar
Permanent URI for this communityhttps://hdl.handle.net/11727/10756
Browse
3 results
Search Results
Item Effects of Combined Visible and Infrared Light Rhinophototherapy in Patients With Allergic Rhinitis(2023) Koycu, Alper; Bas, Ceren; Musabak, Ugur H.; Erbek, Selim Sermed; Koca, Huseyin Samet; Babakurban, Seda Turkoglu; Bahcecitapar, Melike; https://orcid.org/0000-0003-1290-3509; 36266929; AAF-3650-2021Background Intranasal phototherapy offers an alternative treatment method for patients with allergic rhinitis who cannot benefit from intranasal corticosteroids and oral antihistamines. Different wavelengths have been tried with promising results. Objective In this present study, we aimed to investigate the effects of visible light-infrared light phototherapy on clinical improvements together with its cytologic effects in patients with allergic rhinitis. Methods Patients with confirmed allergic rhinitis were given a 4-week course of intranasal phototherapy treatment. Weekly symptom questionnaires were applied to monitor clinical effects. Nasal lavage specimens were obtained before the start and at the completion of the 4-week therapy. Fluorescence-activated cell sorting analyses of CD16(+), CD24(+), and CD 45(+) cells were performed. Statistical analyses are performed of weekly changes in symptoms and cell counts. Results CD45(+)CD16(high)CD24(+) neutrophil count in nasal lavages decreased significantly whereas CD45(+)CD16(dim/-)CD24(+) eosinophil counts significantly increased and CD45(+) granulocyte counts remained unchanged. Symptom scores including nasal itching, nasal discharge, nasal obstruction, sneezing, eye itching, throat itching, and ear itching all statistically decreased compared to baseline at the end of 4 weeks. Conclusion Four-week course of intranasal phototherapy with visible and infrared light leads to clinical improvement in allergic rhinitis patients.Item The Effect of Postmenopausal Osteoporosis on Middle Ear Resonance Frequency(2021) Baytaroglu, Berk; Jafarov, Sabuhi; Erbek, Selim Sermed; 35177390BACKGROUND: The effect of postmenopausal osteoporosis on the middle ear mechano-acoustic system is unknown. The aim of this study is to investigate whether or not middle ear resonance frequency is affected in females with postmenopausal osteoporosis. METHODS: The study included postmenopausal women aged 45-60 years, separated into 2 groups as females with postmenopausal osteoporosis and healthy postmenopausal females (control group). A detailed anamnesis was taken from all subjects and then the ear, nose, and throat examinations were done followed by pure tone audiometry, tympanometry, and multifrequency tympanometry tests. The groups were compared in respect of pure tone average, bone conduction threshold, RF, static admittance, and tympanometric peak pressure values. RESULTS: The mean age of the patients was 59.2 +/- 4.53 years (range, 48-65 years) in the postmenopausal osteoporosis group and 57.11 +/- 4.27 years (range, 48-65 years) in the control group (P>.05). The mean resonance frequency values for the postmenopausal osteoporosis and control group were 954.41 +/- 127.47 and 935.29 +/- 126.39 Hz (P>.05). The mean static admittance values for the postmenopausal osteoporosis and control group were 0.82 +/- 0.33 and 0.85 +/- 0.3 mmho, and mean tympanometric peak pressure values were -7.35 +/- 18.52 and -6.94 +/- 19.52 daPa (P>.05 for both static admittance and tympanometric peak pressure). The mean pure tone averagevalues for the postmenopausal osteoporosis and control group were 20.96 +/- 6.82 and 15.60 +/- 7.81 dB, and mean bone conduction threshold values were 17.57 +/- 6.03 and 12.10 +/- 6.52 dB (P<.05 for both pure tone average and bone conduction threshold). CONCLUSIONS: The results showed that the middle ear resonance frequency values were not affected in postmenopausal osteoporosis patients, but there was seen to be greater sensorineural hearing loss in females with postmenopausal osteoporosis compared to healthy postmenopausal females.Item The differences in the expression of fractalkine and its receptor in conditions of tonsillar hypertrophy and chronic tonsillitis(2019) Hetemoglu, Elif Koclu; Babakurban, Seda Turkoglu; Terzi, Yunus Kasim; Sahin, Feride Iffet; Erbek, Selim Sermed; 0000-0001-5612-9696; 0000-0001-7308-9673; 30554983; B-4372-2018; AAC-7232-2020Objective: Fractalkine, member of chemokine family, is involved in many inflammatory processes in the human body. The aim of this study is to compare expression levels of fractalkine ligand and its receptor in chronic tonsillitis and hypertrophic tonsil samples. Methods: The study was conducted at Baskent University Departments of Otorhinolaryngology and Medical Genetics. It is designed as a prospective, non-randomized, controlled clinical study. Total 97 samples, obtained from adenotonsillectomy due to chronic tonsillitis or tonsillar hypertrophy, were participated in the study. Fractalkine and its receptor expression levels were determined and comparison was made between the tissue groups. c.839C > T (T280 M) polymorphism of fractalkine receptor was analyzed, then relationship between polymorphism and the expression level of fractalkine receptor was investigated. Results: Fractalkine receptor expression was significantly higher in the hypertrophic tonsil group than chronic tonsillitis group (p < 0.05). Conclusion: Fractalkine, member of chemokine family, and its receptor may play role in preventing chronic-recurrent tonsillitis. (C) 2019 Elsevier B.V. All rights reserved.